Health related quality of life · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes health related quality of life compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
Sulphasalazine showed no clear difference in clinical relapse compared with placebo (low certainty).
1 finding from 1 review
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Radiologic relapse · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes adverse events compared with no treatment (very low certainty).
1 finding from 1 review
RR 5 [0.25, 101.81]
110 participants
Very low
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether sulphasalazine changes withdrawal due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Health‐related quality of life (HRQL) · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes withdrawal due to adverse events compared with no treatment (very low certainty).
1 finding from 1 review
Health related quality of life · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · people with surgically‐induced remission in Crohn's disease
5‐ASAs probably leads to lower clinical relapse compared with placebo (moderate certainty).
1 finding from 1 review
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes endoscopic recurrence compared with placebo (very low certainty).
1 finding from 1 review
Global state: any change in global state – unspecified problem necessitating change in dose or type of antipsychotics – medium term · patients with schizophrenia
It is very uncertain whether aspirin plus antipsychotics changes global state: any change in global state – unspecified problem… compared with placebo plus antipsychotics (very low certainty).
1 finding from 1 review
Clinical response: mean score/change in mental state: mean PANSS total score (high = poor) · patients with schizophrenia
1 finding from 1 review
Cognitive functioning Clinically important change in cognitive functioning as defined by each study · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
It is very uncertain whether aspirin plus antipsychotics changes leaving the study early: short‐term – for any reason compared with placebo plus antipsychotics (very low certainty).
1 finding from 1 review
Adverse events: gastrointestinal – dyspeptic symptoms – self‐assessed as at least 'moderate' · patients with schizophrenia
It is very uncertain whether aspirin plus antipsychotics changes adverse events: gastrointestinal – dyspeptic symptoms –… compared with placebo plus antipsychotics (very low certainty).
1 finding from 1 review
Quality of life: clinically important change in quality of life · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found